Discovery: this drug combination increases lifespan by 30% 💊

A combination of human anti-cancer drugs has been shown to increase the lifespan of mice by nearly 30%. This discovery opens up unprecedented prospects for aging research.

The drugs in question, trametinib and rapamycin, have already proven their effectiveness in treating cancer in humans. When administered separately to mice, they demonstrated the ability to extend lifespan, but it was their combination that revealed a remarkable synergistic effect.


Researchers observed that these drugs act on key cellular communication pathways involved in the aging process. Rapamycin targets the mTOR protein, while trametinib interferes with the RAS/Mek/Erk pathway, both of which are involved in cancer cell proliferation.

This study, published in Nature Aging, highlights the potential of these molecules as geroprotective agents. They could not only extend life but also improve the health of elderly individuals by delaying the onset of age-related diseases.

Mice treated with both drugs saw their lifespan increase by up to 29%. This improvement was accompanied by reduced chronic inflammation and delayed cancer development.

The study authors remain cautious about applying these results to humans. However, they are considering clinical trials to evaluate the effectiveness of this combination in humans, particularly for its potential to improve seniors' quality of life.

Optimizing trametinib dosage is a priority for researchers, to maximize its benefits while minimizing side effects. This approach could mark a turning point in how we consider aging treatment.

How can anti-cancer drugs influence aging?

Drugs like rapamycin and trametinib target specific metabolic pathways that play a central role in aging. By inhibiting these pathways, they can slow down degenerative processes associated with age.

Rapamycin, for example, acts on the mTOR protein, a major regulator of cell growth. Its inhibition can reduce inflammation and promote longevity by mimicking the effects of a calorie-restricted diet.

Trametinib, on the other hand, interferes with the RAS/Mek/Erk pathway, involved in cell proliferation. Its action can prevent the accumulation of cellular damage that contributes to aging and chronic diseases.

Together, these drugs could offer a synergistic approach to target multiple aspects of aging simultaneously, paving the way for innovative combination therapies.